We found that ADAM12 activity correlated closely with HB-EGF shedding in endometriosis; therefore, we developed a specific inhibitor of ADAM12 based on its recombinant prodomain (PA12) to reduce HB-EGF shedding, and demonstrated it as effective. This evidence concerns the gene EGF and endometriosis.